The Chemours (NYSE:CC) posted its quarterly earnings data on Sunday. The specialty chemicals company reported $0.71 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.08, MarketWatch Earnings reports. The company had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.40 billion. The Chemours had a positive return on equity of 46.27% and a negative net margin of 2.35%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned $0.71 earnings per share.
NYSE CC traded up $0.28 during mid-day trading on Tuesday, reaching $31.29. The stock had a trading volume of 19,524 shares, compared to its average volume of 1,456,575. The company has a fifty day moving average price of $28.53 and a 200 day moving average price of $26.06. The company has a debt-to-equity ratio of 5.54, a current ratio of 1.99 and a quick ratio of 1.23. The Chemours has a 1 year low of $10.29 and a 1 year high of $32.21. The stock has a market cap of $5.17 billion, a PE ratio of -43.07 and a beta of 2.30.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 15th. Stockholders of record on Monday, May 17th will be issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Friday, May 14th. The Chemours’s payout ratio is 39.84%.
The Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications.
See Also: Float
Receive News & Ratings for The Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Chemours and related companies with MarketBeat.com's FREE daily email newsletter.